Together with our collaborators at the Marcus Institute for Aging Research, an affiliate of Harvard Medical School, Tufts University, and MaineHealth Institute for Research, we were awarded a $3 Million R01 grant from the The National Institutes of Health to evaluate the impact of our lead product, SBD111, in the dietary management of bone health in older women. Congratulations to the entire Solarea Bio team and our collaborators! https://lnkd.in/drR24cgT
Solarea Bio’s Post
More Relevant Posts
-
We are pleased to announce the hiring of Ilissa Larimore as our Chief Commercial Officer. As a seasoned commercial executive, Ilissa will oversee all commercial activities, driving the strategy for sales, marketing, practitioner partnerships and industry collaborations at Solarea. She will focus on advancing new products to market utilizing Solarea's innovative technology platform, with a particular focus on medical foods. We are so excited to have you join us, Ilissa. Welcome to the team!! https://lnkd.in/eKqQjcua
Ilissa Larimore Appointed Chief Commercial Officer at Solarea Bio
prnewswire.com
-
Today we announce the Beta-launch of our first Medical Food product, Bondia, for the dietary management of postmenopausal bone health. Bondia is currently undergoing a large clinical trial in early postmenopausal women, with expected readouts later this summer. The Bondia Medical Food will be commericalized under Solarea's newly unveiled consumer brand, Journa. This is a huge milestone for the Solarea team as we gear up for an anticipated full product launch in September 2024. Stay tuned for more! https://lnkd.in/dU9qHASp
Solarea Bio Announces the Beta Launch of Bondia™, a Novel Daily Medical Food Helping Menopausal Women Manage Bone Loss
prnewswire.com
